Tenx.O

Tenax Therapeutics maintains a conservative capital structure characterized by zero debt and a strong liquidity position. The balance sheet reports total assets of $104.2 million, with cash and equivalents comprising $97.6 million, effectively matching total equity of $97.1 million. Total liabilities stand at a minimal $7.2 million, resulting in a debt-to-equity ratio of 0.0. The company trades at a price-to-book ratio of 1.36, implying the market values the equity slightly above its book value. Despite the strong cash position, the company faces a liquidity risk assessment of "low" in terms of stability, likely due to the absence of revenue generation to sustain operations without capital infusion.

Profitability metrics reflect the pre-revenue stage of the business, with net income at -$52.6 million and operating income at -$56.4 million. Return on equity is -54.19% and return on assets is -50.47%, indicating significant capital consumption relative to the asset base. Operating cash flow is negative at -$35.8 million, highlighting the cash burn rate associated with research and development or general corporate activities. Without cohort median data for comparison, these figures are evaluated in isolation as typical for early-stage biotechnology firms that have not yet commercialized products.

Segment and geographic revenue data are absent, consistent with the reported revenue of $0.0. The company does not disclose a diversified revenue mix, suggesting that all current activity is directed toward product development rather than sales. The lack of segment data precludes analysis of concentration risk or geographic exposure.

Growth trajectory cannot be assessed through historical revenue trends as the company reports zero revenue. The financial snapshot indicates a static share count of 9.31 million basic and diluted shares outstanding. The absence of historical period data prevents the calculation of year-over-year growth rates or trend analysis for net income or revenue.

Risk assessment flags indicate low dilution risk and no immediate filing-based liquidity or dilution flags. The primary risk remains the operational burn rate against the cash reserve. With $97.6 million in cash and a recent operating cash outflow of $35.8 million, the company has a finite runway dependent on future capital raises or milestone achievements. The low confidence in classification (0.20) suggests potential ambiguity in the company's specific business activities or reporting standards.

Recent observations include analyst estimates suggesting a mean price target of $35.22, significantly higher than the current market price of $14.20. The mean recommendation is 1.70, with 3 strong buys and 7 buys, indicating positive sentiment from coverage analysts. News events indicate a reconciler enqueue for analysis, noting zero prior analysis jobs for Tenax Therapeutics Inc.

Operating income −46,2% YoY; Net income −51,0% YoY.

• ▍Operating income −46,2% YoY
• ▍Net income −51,0% YoY

Operating income −125,5% YoY; Net income −148,0% YoY.

• ▍Operating income −125,5% YoY
• ▍Net income −148,0% YoY
• ▍Free cash flow −148,0% YoY

Operating income −263,9% YoY; Net income −299,0% YoY.

• ▍Operating income −263,9% YoY
• ▍Net income −299,0% YoY
• ▍Free cash flow −299,0% YoY

Operating income -$11.8M.

• ▍Operating income -$11.8M

Operating income -$11.3M.

• ▍Operating income -$11.3M

Operating income -$7.3M.

• ▍Operating income -$7.3M

Operating income -$4.6M.

• ▍Operating income -$4.6M

Operating income −189,2% YoY; Net income −198,8% YoY.

• ▍Operating income −189,2% YoY
• ▍Net income −198,8% YoY
• ▍Free cash flow −198,8% YoY

Operating income −136,8% YoY; Net income −128,3% YoY.

• ▍Operating income −136,8% YoY
• ▍Net income −128,3% YoY
• ▍Free cash flow −128,5% YoY

Operating income +25,5% YoY; Net income +30,2% YoY.

• ▍Operating income +25,5% YoY
• ▍Net income +30,2% YoY
• ▍Free cash flow +30,3% YoY

Operating income +66,2% YoY; Net income +66,5% YoY.

• ▍Operating income +66,2% YoY
• ▍Net income +66,5% YoY
• ▍Free cash flow +66,5% YoY